Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases-A prospective randomised placebo-controlled multicentre study

Rotstein, Sam ; Glas, Ulla ; Eriksson, Mikael LU orcid ; Pfeiffer, Per ; Hansen, Jörgen ; Söderqvist, Jonas ; Bandmann, Ulf and Strid, Stig (1992) In European Journal of Cancer 28(4-5). p.890-893
Abstract

In a double blind randomised multicentre study the effect of intravenous clodronate plus hydration was compared with placebo plus hydration in the treatment of hypercalcaemia in breast cancer patients with bone metastases. The patients were treated either with hydration plus clodronate 300 mg/day or hydration plus placebo, up to 7 days or until serum ionised calcium was below 1.4 mmol/l. 25 patients received clodronate and 19 placebo. A significant difference in favour of clodronate was observed in the time to reach normocalcaemia (P = 0.004) and in the number of patients achieving normocalcaemia (P = 0.0003). 17 patients of 21 evaluable patients on clodronate achieved normocalcaemia compared with 4 of 19 patients on placebo. The only... (More)

In a double blind randomised multicentre study the effect of intravenous clodronate plus hydration was compared with placebo plus hydration in the treatment of hypercalcaemia in breast cancer patients with bone metastases. The patients were treated either with hydration plus clodronate 300 mg/day or hydration plus placebo, up to 7 days or until serum ionised calcium was below 1.4 mmol/l. 25 patients received clodronate and 19 placebo. A significant difference in favour of clodronate was observed in the time to reach normocalcaemia (P = 0.004) and in the number of patients achieving normocalcaemia (P = 0.0003). 17 patients of 21 evaluable patients on clodronate achieved normocalcaemia compared with 4 of 19 patients on placebo. The only adverse event clearly associated with clodronate was symptomatic hypocalcaemia in 1 patient. Thus, clodronate seems to be a safe and highly efficacious drug for the treatment of hypercalcaemia in breast cancer patients.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; and
publishing date
type
Contribution to journal
publication status
published
subject
in
European Journal of Cancer
volume
28
issue
4-5
pages
890 - 893
publisher
Elsevier
external identifiers
  • pmid:1388038
  • scopus:0026519585
ISSN
0959-8049
language
English
LU publication?
no
id
f12e9eb5-a54f-43c2-aa6b-3fecb72e81be
date added to LUP
2020-03-30 15:46:40
date last changed
2024-01-02 07:49:36
@article{f12e9eb5-a54f-43c2-aa6b-3fecb72e81be,
  abstract     = {{<p>In a double blind randomised multicentre study the effect of intravenous clodronate plus hydration was compared with placebo plus hydration in the treatment of hypercalcaemia in breast cancer patients with bone metastases. The patients were treated either with hydration plus clodronate 300 mg/day or hydration plus placebo, up to 7 days or until serum ionised calcium was below 1.4 mmol/l. 25 patients received clodronate and 19 placebo. A significant difference in favour of clodronate was observed in the time to reach normocalcaemia (P = 0.004) and in the number of patients achieving normocalcaemia (P = 0.0003). 17 patients of 21 evaluable patients on clodronate achieved normocalcaemia compared with 4 of 19 patients on placebo. The only adverse event clearly associated with clodronate was symptomatic hypocalcaemia in 1 patient. Thus, clodronate seems to be a safe and highly efficacious drug for the treatment of hypercalcaemia in breast cancer patients.</p>}},
  author       = {{Rotstein, Sam and Glas, Ulla and Eriksson, Mikael and Pfeiffer, Per and Hansen, Jörgen and Söderqvist, Jonas and Bandmann, Ulf and Strid, Stig}},
  issn         = {{0959-8049}},
  language     = {{eng}},
  month        = {{01}},
  number       = {{4-5}},
  pages        = {{890--893}},
  publisher    = {{Elsevier}},
  series       = {{European Journal of Cancer}},
  title        = {{Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases-A prospective randomised placebo-controlled multicentre study}},
  volume       = {{28}},
  year         = {{1992}},
}